Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- University of British Columbia
- Registration Number
- NCT05120622
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Davendra Sohal
- Target Recruit Count
- 30
- Registration Number
- NCT05027425
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Simmons Comprehensive Cancer Center UT Southwestern Medical Center, Dallas, Texas, United States
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT05000710
- Locations
- 🇮🇱
Sheba Medical Centre, Ramat Gan, Israel
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 33
- Registration Number
- NCT04988945
- Locations
- 🇭🇰
Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong
🇭🇰The University of Hong Kong, Hong Kong, Hong Kong
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 677
- Registration Number
- NCT04960709
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 31
- Registration Number
- NCT04817826
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Catherine Shu
- Registration Number
- NCT04625699
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Maximilian Diehn
- Target Recruit Count
- 48
- Registration Number
- NCT04585490
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-09-01
- Target Recruit Count
- 55
- Registration Number
- NCT04522544
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Universitätsklinikum Bonn, Bonn, Germany
🇩🇪Universitätsklinikum Freiburg, Freiburg, Germany
Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 18
- Registration Number
- NCT04499053
- Locations
- 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.